女性生殖寿命与激素治疗与晚年神经血管健康的关系
该基于人群的研究纳入352名认知正常的老年女性,发现较长的内源性雌激素暴露(生殖寿命)与较低的脑小血管病负荷相关,外源性雌激素(口服避孕药和绝经激素治疗)与更好的白质完整性和在APOE-ε4携带者中更大的AD相关皮层厚度相关。
要点
- 较长的生殖寿命与较低的脑小血管病负荷独立相关。
- 绝经激素治疗与较少的血管周围间隙和脑微出血相关。
- 口服避孕药和绝经激素治疗联合使用与最高的白质分数各向异性相关。
核心结论
- 终生雌激素暴露(内源性和外源性)与女性较低的脑血管病理相关,且在APOE-ε4携带者中与AD易感区域更大的皮层厚度相关。
研究设计与样本
- 基于人群的队列研究,纳入哥德堡H70-1944出生队列中认知正常的女性,在70岁和5年后进行脑MRI,共352名女性(平均年龄70岁)。
主要发现
- 较长的生殖寿命与较低的脑小血管病负荷相关(OR=0.92,95%CI 0.86-0.99)。
- 绝经激素治疗与较少的血管周围间隙和脑微出血相关。
- 口服避孕药和绝经激素治疗与更高的白质完整性相关,联合使用者的分数各向异性最高(β=0.45,95%CI 0.12-0.78)。
- 仅在APOE-ε4携带者中,绝经激素治疗与更大的AD相关皮层厚度相关(β=0.38,95%CI 0.01-0.76)。
- 较长的雌激素暴露与皮层厚度和白质高信号轨迹的稳定相关。
临床怎么用
- 对于老年女性,评估生殖寿命和激素使用史可能有助于识别脑血管病理和AD相关脑改变的风险。
- 在APOE-ε4携带者中,绝经激素治疗可能与AD相关皮层厚度获益相关,但需个体化评估。
局限性
- 观察性设计。
- 雌激素暴露为自我报告的二分变量。
- 潜在的认知影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Women are disproportionately affected by Alzheimer disease (AD), a vulnerability that may relate to estrogen fluctuations across the lifespan. Estrogen has neuroprotective and vasoprotective effects, suggesting that lifetime estrogen exposure may influence both AD-related neurodegeneration and cerebrovascular health. However, its association with late-life vascular and neurodegenerative brain changes remains unclear. We aimed to examine the associations of lifelong estrogen exposure-endogenous (reproductive span) and exogenous (oral contraceptives [OCs], menopausal hormone therapy [MHT])-with late-life vascular brain injury and AD-related atrophy and explore apolipoprotein-ε4 (APOE-ε4) effects. METHODS: This population-based study included cognitively unimpaired women from the Gothenburg H70-1944 Birth Cohort who underwent brain MRI at age 70 and again 5 years later. Reproductive lifespan was calculated as age at menopause or oophorectomy minus age at menarche. OC and MHT use were categorized as ever vs never users. Outcomes included cerebral small vessel disease (SVD), AD-related cortical thickness, and white matter integrity (fractional anisotropy). SVD burden was a composite score derived from white matter hyperintensities (WMHs), lacunes, cerebral microbleeds (CMBs), and perivascular spaces (PVSs) (range 0-4). Linear, multinomial, and mixed-effects regression models were adjusted for relevant confounders and stratified by APOE-ε4. RESULTS: Among 352 women (mean age 70 years), longer reproductive span was associated with lower SVD burden (OR = 0.92, 95% CI 0.86-0.99). MHT use was associated with fewer PVSs and CMBs. OC and MHT use were associated with greater white matter integrity, with combined use showing the highest fractional anisotropy compared with nonusers (β = 0.45, 95% CI 0.12-0.78). No multiplicative interaction between OCs and MHT was observed, although joint exposure analyses suggested cumulative effects. MHT use was associated with greater AD-related cortical thickness among APOE-ε4 carriers only (β = 0.38, 95% CI 0.01-0.76). Longer estrogen exposure was associated with stable cortical thickness and WMH trajectories over time. DISCUSSION: Greater lifetime estrogen exposure, both endogenous and exogenous, was associated with lower cerebrovascular pathology in women and, among APOE-ε4 carriers, greater cortical thickness in AD-vulnerable regions. These findings support the potential role of cerebrovascular mechanisms linking estrogen exposure to brain aging. Limitations included observational design and self-reported, binary estrogen exposure. Potential cognitive effects require further studies.
引用
- Lorenzon G, Garcia-Lluch G, Coughlan GT, et al. Reproductive Lifespan and Hormonal Therapy in Relation to Later-Life Neurovascular Health in Community-Dwelling Older Women. Neurology. 2026. PMID: 42981558. doi:10.1212/WNL.0000000000218706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。